Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03283683
Other study ID # 16ONCN0004
Secondary ID
Status Completed
Phase
First received
Last updated
Start date May 25, 2016
Est. completion date October 19, 2018

Study information

Verified date March 2019
Source Royal Surrey County Hospital NHS Foundation Trust
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study evaluates the use of actigraphy-derived measures to improve prognostication in patients with advanced cancer.


Description:

An accurate assessment of prognosis (life expectancy) is important for cancer patients, their carers, and their health care professionals. In the case of patients / their carers, it allows them to plan for the future, and to make more informed decisions about further anti-cancer treatments, and about referral to supportive and palliative care services. However, previous research suggests that health care professionals are not particularly good at estimating prognosis, and frequently over-estimate prognosis.

The aim of this project is to assess the usefulness of measuring physical activity, and differences between daytime and nighttime physical activity, in determining prognosis in patients with cancer. Studies suggest that these measures may be useful in determining prognosis in certain groups of patients with cancer (e.g. patients receiving chemotherapy for colon / rectum cancer). However, these studies need to be repeated in patients with different types of cancer, and also patients receiving other types of treatment (including supportive and palliative care). The aim of this small scale ("feasibility") study is to determine whether or not a large scale ("definitive") study can be done.

The feasibility study will include 50 patients with cancer, who will be asked to rate their performance status (physical activity) on a well-used scale, and then to wear a watch-like device for one week that measures physical activity and sleep patterns. The researcher will collect a blood sample: some of which will be used for analysis of parameters, which have previously been identified as prognostic indicators and will collect and store some blood for future transcriptome analysis. Participants will also be asked to complete a sleep diary during the week, and a questionnaire about their symptoms at the beginning and end of the week. The study will last one week in total and is collaboration between the Royal Surrey County Hospital, and the University of Surrey (Surrey Sleep Research Centre).


Recruitment information / eligibility

Status Completed
Enrollment 50
Est. completion date October 19, 2018
Est. primary completion date October 19, 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Outpatients.

- Age = 18 years.

- Diagnosis of locally advanced / metastatic cancer.

- No curative treatment available.

- Patient receiving supportive and palliative care.

- Negative response from palliative medicine physician to the "surprise" question (i.e. "would you be surprised if this patient were to die in the next 12 months").

- (Estimated) prognosis of > 2 weeks.

Exclusion Criteria:

- Inpatients.

- Age < 18 years.

- Diagnosis of local (non-advanced) cancer.

- Curative treatment available.

- Presence of a physical disability that affects daytime activity (e.g. metastatic spinal cord compression).

- Presence of a physical disability that affects movement of the non-dominant arm (e.g. lymphoedema).

- Cognitive impairment (clinical judgement).

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United Kingdom Royal Surrey County Hospital Guildford Surrey

Sponsors (1)

Lead Sponsor Collaborator
Royal Surrey County Hospital NHS Foundation Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Other Actigraphy-derived sleep parameters Parameters during the presumed sleep phase of the circadian cycle; eg: Time in bed, sleep efficiency e.t.c 7 days
Other Physician ECOG-PS Physician's assessment of the patient's ECOG-Performance Status. The Eastern Cooperative Oncology Group performance scale (ECOG-PS) is a standardised measure for quantifying the functional status of patients with cancer and includes a numerical / categorical scale Day 0 actigraphy and Day 8 actigraphy
Other Patient ECOG-PS Patient's assessment of their own ECOG-Performance Status Day 0 actigraphy and Day 8 actigraphy
Other Memorial Symptom Assessment Scale - Short Form (MSAS-SF) The MSAS-SF is a validated symptom assessment tool that has been used extensively in oncology / palliative care research and includes questions on both physical and psychological symptoms. Day 0 actigraphy and Day 8 actigraphy
Other Pittsburgh Sleep Quality Index (PSQI) This is a validated, self-rated questionnaire, which measures sleep quality and disturbances over a 1-month time period Day 8 actigraphy
Other Prognosis in Palliative Care Study predictor model (PiPS-B model) Compare actigraphy-derived circadian / sleep parameters against other validated prognostic indicators Day 0 actigraphy
Other modified Glasgow Prognostic Score (mGPS) Compare actigraphy-derived circadian / sleep parameters against other validated prognostic indicators Day 0 actigraphy
Primary Dichotomy Index (I<O) Compares the amount of activity of the patient when in bed to when the patient is out of bed. An actigraphy-derived percentage of the activity counts, measured when the patient is in bed, that are inferior to (lower than) the median of the activity counts measured when the patient is out of bed. 7 days.
Secondary r24 An actigraphy-derived 24hr correlation coefficient that reports on how reproducible the patient's activity is every 24 hours. upto 7 days
Secondary mean or average activity calculated as the average number of wrist movements per minute throughout the recording time 7 days.
See also
  Status Clinical Trial Phase
Recruiting NCT05346796 - Survivorship Plan HEalth REcord (SPHERE) Implementation Trial N/A
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT04867850 - Effect of Behavioral Nudges on Serious Illness Conversation Documentation N/A
Enrolling by invitation NCT04086251 - Remote Electronic Patient Monitoring in Oncology Patients N/A
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00062842 - Study of Irinotecan on a Weekly Schedule in Children Phase 1
Active, not recruiting NCT04548063 - Consent Forms in Cancer Research: Examining the Effect of Length on Readability N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04349293 - Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways N/A
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Active, not recruiting NCT05304988 - Development and Validation of the EFT for Adolescents With Cancer
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Recruiting NCT06206785 - Resting Energy Expenditure in Palliative Cancer Patients
Recruiting NCT05318196 - Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases